Fibroblast growth factor 21 is an independent predictor of prevalent and incident obstructive sleep apnea

被引:3
作者
Huang, Weijun [1 ,2 ,3 ]
Zhang, Jingyu [1 ,2 ,3 ]
Zou, Jianyin [1 ,2 ,3 ]
Wang, Xiaoting [1 ,2 ,3 ]
Xu, Huajun [1 ,2 ,3 ]
Guan, Jian [1 ,2 ,3 ]
Yi, Hongliang [1 ,2 ,3 ]
Liu, Suru [1 ,2 ,3 ]
Yin, Shankai [1 ,2 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Dept Otorhinolaryngol Head & Neck Surg, Shanghai Peoples Hosp 6, Sch Med, 600 Yishan Rd, Shanghai, Peoples R China
[2] Shanghai Key Lab Sleep Disordered Breathing, 600 Yishan Rd, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Otolaryngol Inst, 600 Yishan Rd, Shanghai, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
NONALCOHOLIC FATTY LIVER; INSULIN SENSITIVITY; METABOLIC SYNDROME; GLUCOSE-TOLERANCE; LIPID-METABOLISM; RISK-FACTOR; OBESITY; POPULATION; HYPOPNEA; DISEASE;
D O I
10.1016/j.isci.2023.105985
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fibroblast growth factor 21 (FGF21) is a metabolic regulator and a potential biomarker of metabolic diseases. Limited data are available on the association between FGF21 and obstructive sleep apnea (OSA), which is considered as a manifestation of metabolic syndrome. In the present cross-sectional and longi-tudinal analyses, the FGF21 level was associated with OSA. This analysis of two clinical cohorts is the first to show that the FGF21 level increased signifi-cantly with OSA severity and was an independent predictor of incident OSA in Chinese adults. The circulating FGF21 level could serve as a potential serum biomarker of OSA and its comorbidities and thus aid risk evaluation and early intervention.
引用
收藏
页数:19
相关论文
共 62 条
[11]   Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 [J].
Degirolamo, Chiara ;
Sabba, Carlo ;
Moschetta, Antonio .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (01) :51-69
[12]   βKlotho Is Required for Fibroblast Growth Factor 21 Effects on Growth and Metabolism [J].
Ding, Xunshan ;
Boney-Montoya, Jamie ;
Owen, Bryn M. ;
Bookout, Angie L. ;
Coate, Katie Colbert ;
Mangelsdorf, David J. ;
Kliewer, Steven A. .
CELL METABOLISM, 2012, 16 (03) :387-393
[13]   Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease [J].
Dushay, Jody ;
Chui, Patricia C. ;
Gopalakrishnan, Gosala S. ;
Varela-Rey, Marta ;
Crawley, Meghan ;
Fisher, Ffolliott M. ;
Badman, Michael K. ;
Martinez-Chantar, Maria L. ;
Maratos-Flier, Eleftheria .
GASTROENTEROLOGY, 2010, 139 (02) :456-463
[14]  
Epstein LJ, 2009, J CLIN SLEEP MED, V5, P263
[15]   Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State [J].
Fisher, Ffolliott M. ;
Chui, Patricia C. ;
Antonellis, Patrick J. ;
Bina, Holly A. ;
Kharitonenkov, Alexei ;
Flier, Jeffrey S. ;
Maratos-Flier, Eleftheria .
DIABETES, 2010, 59 (11) :2781-2789
[16]   Estimation of the Youden index and its associated cutoff point [J].
Fluss, R ;
Faraggi, D ;
Reiser, B .
BIOMETRICAL JOURNAL, 2005, 47 (04) :458-472
[17]   Obstructive sleep apnea and the metabolic syndrome: The road to clinically-meaningful phenotyping, improved prognosis, and personalized treatment [J].
Gaines, Jordan ;
Vgontzas, Alexandros N. ;
Fernandez-Mendoza, Julio ;
Bixler, Edward O. .
SLEEP MEDICINE REVIEWS, 2018, 42 :211-219
[18]   The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic [J].
Geng, Leiluo ;
Lam, Karen S. L. ;
Xu, Aimin .
NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (11) :654-667
[19]   Fibroblast growth factor-21, energy balance and obesity [J].
Giralt, Marta ;
Gavalda-Navarro, Aleix ;
Villarroya, Francesc .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 :66-73
[20]   Prospective Study of Obstructive Sleep Apnea and Incident Coronary Heart Disease and Heart Failure The Sleep Heart Health Study [J].
Gottlieb, Daniel J. ;
Yenokyan, Gayane ;
Newman, Anne B. ;
O'Connor, George T. ;
Punjabi, Naresh M. ;
Quan, Stuart F. ;
Redline, Susan ;
Resnick, Helaine E. ;
Tong, Elisa K. ;
Diener-West, Marie ;
Shahar, Eyal .
CIRCULATION, 2010, 122 (04) :352-360